Momenta Pharmaceuticals, Inc. (MNTA) Receives Orphan Drug Designation For Necuparanib (Formerly M402) In Pancreatic Cancer
6/5/2014 9:24:04 AM
CAMBRIDGE, Mass., June 5, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today announced that its novel oncology candidate, necuparanib (formerly M402), has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer.
Help employers find you! Check out all the jobs and post your resume.
comments powered by